Drugs / Camonsertib
Trials 9
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07156227 | Feb 2027 → May 2029 expected | hypopharynx squamous cell carcinoma, laryngeal squamous cell carcinoma, oral cavity squamous cell carcinoma, oropharynx squamous cell carcinoma +1 | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
| Phase 1 | NCT04855656 | Apr 2021 → Dec 2027 expected | neoplasm | Debiopharm International SA | Recruiting | No outcome recorded |
| Phase 1/25 trials | ||||||
| Phase 1/2 | NCT05566574 | Sep 2022 → Sep 2026 overdue | metastatic malignant neoplasm | Memorial Sloan Kettering Cancer Center | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT05405309 | Sep 2022 → Oct 2023 | chronic lymphocytic leukemia/small lymphocytic lymphoma | University of Utah | Terminated | No outcome recorded |
| Phase 1/2 | NCT04972110 | Jul 2021 → Nov 2024 | — | Repare Therapeutics | Terminated | No outcome recorded |
| Phase 1/2 | NCT04497116 | Jul 2020 → Jun 2025 | neoplasm | Repare Therapeutics | Completed | No outcome recorded |
| Phase 1/2 | NCT03337698 | Dec 2017 → Oct 2025 | non-small cell lung carcinoma | Hoffmann-La Roche | Terminated | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT05601440 | Jun 2023 → Dec 2027 expected | female breast carcinoma | Canadian Cancer Trials Group | Recruiting | No outcome recorded |
| Phase 2 | NCT04589845 | Jan 2021 → Sep 2032 expected | cancer | Hoffmann-La Roche | Active not recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT05605509 Comparator | May 2023 → Nov 2025 | cancer of unknown primary site | Canadian Cancer Trials Group | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 13 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | camonsertib | “RP-3500 (camonsertib, ATR inhibitor) in combination with niraparib or olaparib (PARP inhibitors)” NCT04972110 ↗ |
| Known as | ATR INHIBITOR 4 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095260 ↗ |
| Known as | RP-3500 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04855656 ↗ |
| Action | Inhibit | “selective oral inhibitor of ataxia telangiectasia and Rad3-related (ATR) kinase” PMID 38710487 ↗ Sep 2024 |
| Modality | Small molecule | — CHEMBL5095260 ↗ |
| Route | Oral | “Camonsertib is administered orally on Days 1-3, Days 8-10 of a 21 day cycle.” NCT03337698 ↗ |
| Target | ATR | “selective oral inhibitor of ataxia telangiectasia and Rad3-related (ATR) kinase” PMID 38710487 ↗ Sep 2024 |